Friday, April 2, 2021 Single-Dose COVID-19 Nasal Vaccine Limits Infection in Monkeys Image caption: This scanning electron microscope image shows SARS-CoV-2 (round gold objects) emerging from the surface of cells cultured in the lab. SARS-CoV-2 is the virus that causes COVID-19. The virus shown was isolated from a patient in the U.S. Single-Dose COVID-19 Nasal Vaccine Limits Infection in Monkeys NIAID scientists and Washington University colleagues have shown that a single dose of an experimental COVID-19 vaccine delivered into the nose of rhesus macaques protected their lungs and nasal region from SARS-CoV-2 infection. Their new study,  published in Cell Reports Medicine, expands on work done in mice and hamsters. The vaccine, known in its pre-clinical formulation as ChAd-SARS-CoV-2-S, is undergoing clinical trials in India under the name BBV154. The vaccine uses an adenoviral vector that infects chimpanzees to deliver the genetic information for an immune-stimulating protein from SARS-CoV-2, the virus that causes COVID-19. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107